HanA.KohMD

Oncology • Moreno Valley, CA

Specializes in hematology / oncology, medical oncology, internal medicine in Moreno Valley, California. Associate Professor of Medicine at Loma Linda University Medical School.

Join to view full profile

Dr. Koh is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Koh's full profile

Already have an account?

Office
26520 Cactus Ave
Moreno Valley, CA 92555
Phone+1 951-486-4000
Is this information wrong?

Education & Training

Cedars-Sinai Medical CenterFellowship, Hematology and Medical Oncology, 1995 - 1996
Los Angeles County-Harbor-UCLA Medical CenterResidency, Internal Medicine, 1990 - 1993
Saint Louis University School of MedicineClass of 1990

Certifications & Licensure

CA State Medical License 1991 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011

Clinical Trials

Cytogenetic Studies in Acute Leukemia and Multiple Myeloma Start of enrollment: 1984 Jun 01
Active, not recruiting
Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab Start of enrollment: 2006 Mar 01
Completed
Phase 2
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
Completed
Phase 3
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
Active, not recruiting
Phase 3
Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma Start of enrollment: 2007 Nov 15
Completed
Phase 2
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor Start of enrollment: 2007 Dec 01
Active, not recruiting
Phase 3
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
Active, not recruiting
Phase 3
Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy Start of enrollment: 2008 Jun 15
Completed
Phase 3
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Start of enrollment: 2008 Apr 15
Completed
Phase 2
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Start of enrollment: 2008 Oct 13
Completed
Phase 3
S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma Start of enrollment: 2009 Jul 01
Completed
Phase 2
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Jan 29
Active, not recruiting
Phase 3
Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes Start of enrollment: 1996 May 01
Active, not recruiting
Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2009 Oct 01
Completed
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2010 Feb 15
Completed
Phase 3
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
Active, not recruiting
Phase 3
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy Start of enrollment: 2010 Sep 15
Terminated
Phase 3
Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery Start of enrollment: 2010 Oct 15
Completed
Phase 2
Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance Start of enrollment: 2011 Jan 01
Completed
Phase 3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec'v Hormone Thpy Start of enrollment: 2012 Feb 01
Completed
Phase 3
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery Start of enrollment: 2014 Feb 01
Completed
Phase 2
A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib Start of enrollment: 2014 Jun 04
Completed
Phase 2
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 22
Active, not recruiting
Phase 3
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Join now to see all

Publications & Presentations

PubMed

1 citations
Leukemic infiltration of the optic nerve in chronic lymphocytic leukemia: A case report and review of literature.
Louisa Liu, Annie Park, Mojtaba Akhtari, Jonathan Scott, Dani Ran-Castillo, Esther Chong, Han Koh, Karlos Oregel, Keerti Khandelwal, Rahel Demisse, Hadyah, S.> ;Leukemia Research Reports. 2023 Jan 1
3 citations
MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR +, HER2 --Advanced Breast Cancer
Patrick Neven, Stephen R. D. Johnston, Masakazu Toi, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, Meena Okera, Norikazu Masuda, Peter A. Kaufman, Han Koh,...> ;Clinical Cancer Research. 2021 Nov 1
13 citations
Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples.
Scott A. Tomlins, Daniel H. Hovelson, Jennifer Marie Suga, Daniel M. Anderson, Han A. Koh, Elizabeth Claire Dees, Brendan McNulty, Mark E. Burkard, Michael Guarino, Ja...> ;JCO Precision Oncology. 2021 Aug 19
37 citations
MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Can...
Aparna Raj Parikh, Fa-Chyi Lee, Linda Yau, Han Koh, James A. Knost, Edith P. Mitchell, Ivan Bosanac, Nicholas Choong, Frank A. Scappaticci, Christoph Mancao, Heinz-Jos...> ;Clinical Cancer Research. 2019 May 15
5 citations
Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system
Nazia Rashid, Han A. Koh, Kathy J Lin, Brian Stwalley, Eugene Felber> ;Journal of Oncology Pharmacy Practice. 2018 Jun 1
903 citations
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
George W. Sledge, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, Meena Okera, Norikazu Masuda, Peter A. Kaufman, Han Koh, EM Gr...> ;Journal of Clinical Oncology. 2017 Jun 3
53 citations
Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system.
Nazia Rashid, Han A. Koh, Hilda C. Baca, Kathy J Lin, Susan E Malecha, Anthony Masaquel> ;Breast Cancer. 2016 Oct 4
27 citations
Clinical Impact of Chemotherapy-Related Adverse Events in Patients with Metastatic Breast Cancer in an Integrated Health Care System.
Nazia Rashid, Han A. Koh, Hilda C. Baca, Zhaoliang Li, Susan E Malecha, Oyewale O. Abidoye, Anthony Masaquel> ;Journal of Managed Care & Specialty Pharmacy. 2015 Oct 19
14 citations
Suramin enters and accumulates in low pH intracellular compartments of v-sis-transformed NIH 3T3 cells
Shuan Shian Huang, Han A. Koh, Jung San Huang> ;FEBS Letters. 1997 Oct 27
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Hospital Affiliations

Riverside University Health System-Medical CenterMoreno Valley, California